Are you one of the millions about to have cataract surgery? Here’s what ophthalmologists say you need to know
(THE CONVERSATION) Cataract surgery is one of the most popular and commonly performed procedures in the world. The vast majority of patients have excellent outcomes with few complications. By age 80, ...
Kids are becoming nearsighted by screens. Annual school eye exams can help.
Myopia in students is a serious concern, especially with online learning, an IndyStar reader writes in a letter to the editor ...
Breakthrough Study Reveals Somavedic Device's Potential Impact on Wet AMD Patients
Somavedic, a trailblazer in sleep and digital pollution-neutralizing frequency therapy technology, in collaboration with ...
Verywell Health on MSN1y
How to Talk About Age-Related Macular Degeneration (AMD)
Medically reviewed by Christine L. Larsen, MD If you've recently been diagnosed with age-related macular degeneration (AMD), even while you're still processing your diagnosis you're also likely trying ...
Stockhead on MSN1d
Dr Boreham’s Crucible: In rare Phase 3 air, can Opthea now see its way clear to a $15bn market?
Back-of-the eye treatment company Opthea has taken this lore to heart, having rolled out three key opinion leaders – eye ...
Pharmabiz3h
Bayer to present new long-term results and subgroup analyses from pivotal clinical trial of Eylea 8 mg in nAMD & DME at ARVO meeting
A post-hoc analysis of the PULSAR phase III trial assesses if key baseline disease characteristics such as BCVA, central retinal thickness (CRT), and total choroidal neovascularization (CNV) lesion ...
Insurer made to pay for intravitreal injection
Ahmedabad: The Consumer Disputes Redressal Commission (CDRC) has ordered United India Insurance Co Ltd to reimburse a patient ...
Channel NewsAsia Singapore12d
These public-private partnerships are helping to improve eye care across Asia, in line with the UN resolution to achieve 'Vision for Everyone' by 2030
“WITHIN ASIA, SOME HEALTHCARE SYSTEMS CURRENTLY FALL SHORT IN ADEQUATELY SERVING EYE PATIENTS. KEY BARRIERS INCLUDE A LIMITED ...
Pharmabiz14d
Chugai Pharma announces Japanese phase III study of Vabysmo for angioid streaks associated with neovascularization meets primary endpoint
Chugai Pharma announces Japanese phase III study of Vabysmo for angioid streaks associated with neovascularization meets primary endpoint: Tokyo Tuesday, April 16, 2024, 12:00 Hrs ...
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study ...
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and ...